Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 11593 - 11600 of 12007 results

The HIPAA Auditors Are Coming! The HIPAA Auditors Are Coming!
July 12, 2011| Blog| Viewpoint

Leaves of Absence as Reasonable Accommodation: Verizon pays $20MM for "No Fault" Attendance Policy
July 8, 2011| Blog| Viewpoint

FTC Announces $1.8 Million Settlement for Violation of Fair Credit Reporting Act
June 30, 2011| Blog| Viewpoint

Supreme Court's Ruling in Wal-Mart v Dukes is a Big Victory for Employers
June 28, 2011| Blog| Viewpoint

EEOC Holds Public Hearing on Use of Medical Leaves of Absence as "Reasonable Accommodation"
June 21, 2011| Blog| Viewpoint

Supreme Court "Makes" Securities Fraud Recovery More Difficult
June 16, 2011| Blog| Viewpoint

"Reasonable" security does not necessarily equal "best" security - even if ACH fraud involved
June 16, 2011| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|

Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|
